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Abstract 
Introduction: Hormone replacement therapy (HRT) and walking were investigated independently 
and in combination, to determine which treatment provided most effect on bone turnover in post-
menopausal women.  
Methods: Using a randomised double-blind pilot study, 10 subjects received HRT (transdermal 
estradiol, 50 µg/day and oral MPA 5 mg/day) and 12 received placebo for 20 weeks. Following a 
baseline period of treatment, both groups undertook a graduated walking regimen, which increased 
in intensity, duration and frequency parameters from weeks 8–20. Measurements of aerobic capacity, 
female sex hormones, bone formation markers [osteocalcin (OC) and bone alkaline phosphatase 
(BAP)] and bone resorption markers [deoxypyridinoline (DPD) and pyridinoline (PYR)] were 
measured at baseline (T1), week 8 (T2) and week 20 (T3).  
Results: Age, time of postmenopause, weight or body mass index were no different between each 
groups. The HRT group had significantly higher estradiol levels compared with the placebo group at 
T2 and T3. FSH and LH levels were significantly reduced following HRT. DPD and PYR were sig-
nificantly reduced from baseline levels at T2 and T3 with HRT. No significant changes occurred in 
OC or BAP levels with either HRT or walking. Walking did not change bone turnover markers in 
either the HRT or placebo group.  
Conclusion: HRT reduces bone resorption, however, walking alone at the intensity and duration pres-
cribed, or the combination of HRT and walking, provided no additional benefit after menopause. There-
fore, HRT, but not walking is an effective treatment in reducing bone turnover in postmenopause women.  
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Introduction 
Menopause is associated with endocrine 
changes, including significant reductions in estro-
gen and progesterone levels, and alterations in 
the pituitary gonadotrophins, follicle stimulating 
hormone (FSH) and leutinising hormone (LH). 
Other age associated changes that occur with 
ageing, that are superimposed on estrogen defi-
ciency include elevated serum parathyroid hor-
mone (PTH) and attenuated calcitriol levels. 
These changes have been implicated in altered 
bone metabolism and reduced skeletal integrity 
after menopause. 
Bone metabolism can be assessed by the 
measurement of biochemical markers that are 
released into the circulation and urine, provi-
ding chemical indices for whole body bone tur-
nover [1–9]. The level of these biochemical 
markers can predict bone density and rates of 
bone loss in postmenopausal populations [10]. 
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The relationship of bone turnover markers to 
changes in bone mineral density (BMD) is in-
verse in states of altered bone remodeling [11], 
providing a cost effective, potentially useful 
tool for the prediction of the bone responses to 
changes in bone remodeling [11].  
Menopause is associated with a 79–97% 
increase in bone resorption markers, whilst bone 
formation markers are increased by 37–52%, 
reflecting an overall increase in bone turnover 
[12]. Alterations in bone turnover markers pre-
cede changes in bone mass and density. BMD 
is reduced in the initial 3 to 12 months after the 
last menses by 0.9% at the lumbar spine and 
0.7% in the femoral neck [13]. This attenuation 
of bone is associated with reduced circulating 
estrogen levels. The bone loss experienced in the 
initial 6 years after menopause is estimated to 
be approximately 15% [14], imposing a conside-
rable risk for the development of osteoporosis.  
Increasing age is typically associated with 
reduced levels of physical activity. A reduction 
in weight bearing exercise, and less frequent 
involvement in exercise that provides mechanical 
loading on bones, are potentially associated with 
lowered bone density and an increased risk of 
fracture. This is shown in immobility [15] and 
space flight [16] studies where there is little or no 
mechanical strain or loading on bone and a sub-
sequent deterioration in bone density occurs. 
Hormonal replacement therapy (HRT) con-
taining estrogen, and physical activity are com-
monly prescribed as independent interventions 
for reducing the risk of osteopenia after meno-
pause. Estrogen plays a major role in bone me-
tabolism and cytokines production, which ma-
intains the quality of bone and alveolar bone 
crest [17]. The signal transduction pathways 
for estrogen and the mechanical strain appear 
to share common elements [18], and both inter-
ventions may be relevant in the prevention of 
postmenopausal osteoporosis.  
The most effective type and intensity of 
exercise, to provide the greatest benefit to bone 
whilst fostering compliance, remain to be fully 
elucidated. Whilst bone mineral density (BMD) 
and HRT have been extensively researched, 
there has been little investigation into bone tur-
nover changes as a result of exercise either in-
dependently, or combining these 2 interven-
tions in a postmenopausal population. We pro-
posed that moderate exercise in the form of 
brisk walking would induce a weight-bearing 
mechanical load on bone, whilst providing an 
accessible and safe form of exercise for women 
who do not participate in any regular or struc-
tured form of exercise. Herein, we evaluated 
the effect of low intensity exercise in the form 
of walking and HRT independently, and when 
combined, on bone turnover markers in post-
menopausal sedentary women. 
 
Methods 
Postmenopausal subjects 
Twenty eight postmenopausal women were 
recruited from the general public via advertise-
ments in local papers. Six women withdrew 
from the study; one woman moved away du-
ring the course of the study; two women suf-
fered skin irritation caused from the transder-
mal estrogen; two women withdrew due to lack 
of time available to continue involvement; one 
woman was excluded prior to commencement 
due to excessive alcohol intake. Twenty two 
women completed the study. The criteria for 
inclusion were 1–5 years postmenopause; aged 
between 45–60 years. The criteria for exclusion 
were; taking any form of hormonal replace-
ment therapy; previous hysterectomy or oopho-
rectomy; family history of estrogen dependent 
malignancies; established cardiovascular disease; 
involved in any regular form of structured exer-
cise; smoking; taking any drug therapy or ha-
ving any disease that would affect the gain/loss 
of bone mineral. All women were cleared for 
participation following a full physical examina-
tion by a clinician. 
Women were randomly assigned into 2 
groups. Ten women were assigned into the 'HRT 
group', and commenced using transdermal estra-
diol patches (Estraderm 50 µg, Novartis Phar-
maceuticals, North Ryde, NSW, Australia) chan-
ged twice weekly, and oral medroxyprogeste-
rone acetate (MPA, 5mg/day) (Pharmacia Phar-
maceuticals, Rydalmere, NSW, Australia). Twel-
ve women were assigned to the 'placebo' group 
and commenced using placebo transdermal pat-
ches and oral placebo tablets. All subjects par-
ticipating in this study were asked to maintain 
their current dietary habits throughout their in-
volvement in the study. All women gave infor-
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med consent to participate in this study, which 
was approved by the Human Ethics Commit-
tee, Victoria University (991017/CO484). 
Protocol 
Subjects were tested three times over the 
duration of the twenty week study. Measure-
ments were taken at baseline (Tl), prior to com-
mencement of exercise training, at eight weeks 
(T2) and on completion of the study, at twenty 
weeks (T3). Height and weight were determi-
ned for all subjects. At each time point, aerobic 
capacity was determined by measures of V02 
peak. In addition, morning fasting blood samples 
were taken for measurement of estradiol, leu-
tinising hormone (LH) and follicle stimulating 
hormone (FSH) and bone formation markers, 
bone alkaline phosphatase (BAP) and osteocal-
cin (OC). Urine samples were taken 2 hours 
post first morning void, at the above intervals 
for measurement of the bone resorption markers, 
pyridinoline (PYR) and deoxypyridoline (DPD).  
Subjects continued their specified treat-
ment regimen throughout the 20 week period. 
After 8 weeks, subjects initiated an exercise 
training program whilst continuing their speci-
fied treatment regimen. This program was indi-
vidually based on each participant's baseline 
fitness level. From baseline aerobic capacity 
measures, volume of expired carbon dioxide 
(ml/kg/min) was plotted against the volume of 
expired oxygen (ml/kg/min). A parallel graph, 
plotting ventilation (L/min) against oxygen con-
sumption (ml/kg/min) was determined for the 
duration of the test. A non-linear fit was asses-
sed for each graph and the maximum of the 
second derivative was determined as the inflec-
tion point, noted as the anaerobic threshold. 
The heart rate at anaerobic threshold was used 
to calculate the training heart rate. Individuals 
underwent a 12 week walking program. Exer-
cise intensities assessed by heart rate monito-
ring commenced at 70% of the baseline anaero-
bic threshold and increased by 5% every second 
week to 95% of anaerobic threshold over the 
following 12 week period. The participants 
achieved the increments in heart rate by increa-
sing the speed of walking, or walking on an 
incline. The duration of exercise at the speci-
fied heart rate commenced at 10 minutes and 
increased by 5 minutes duration every second 
week to a total of 35 minutes at twenty weeks. A 
5 minute warm up and cool down preceded and 
followed each walking session. Lastly, the fre-
quency of exercise sessions performed per week 
commenced at three, and increased by one ses-
sion per week on a monthly basis. Two women 
suffered skin irritation caused from the transder-
mal estrogen, whilst there were no adverse effects 
of involvement in the walking program. 
Assays 
Estradiol was measured using a competi-
tive chemiluminescent immunoassay (Ciba Co-
ming, Medfield, MA, USA). FSH and LH were 
measured using a two-site chemiluminescent 
(sandwich) immunoassay (Ciba-Coming, Medfi-
eld, MA, USA). BAP was measured using the 
standard autoanalyser ELISA technique (Alka-
phase B96, Metra Biosystems). Serum OC was 
measured by radioimmunoassay using the osteo-
calcin RIA kit (Incstar Corp., Stillwater, MN, 
USA). Free PYR and DPD cross links were mea-
sured on morning void urine samples by an enzy-
me linked immunosorbent assay (ELISA) using 
rabbit antipyridinoline (Pyrilinks, Metra Biosys-
tems, Palo Alto, CA, USA) and expressed as py-
ridinoline/creatinine ratio (PYR nmol/mmol Cr). 
Aerobic Capacity 
Aerobic fitness was determined via a V02 
peak test. This test measures oxygen consum-
ption per minute during exercise to peak levels. 
Measurement to maximum levels was deemed 
less safe within this population. Hence, a V02 
peak test was used instead of a V02 max pro-
tocol. The laboratory where the trials were con-
ducted was maintained at a constant tempera-
ture (20 ± 1°C) and humidity (44 ± 2%). A 12 
lead electorcardiogram (ECG; Montara, X-scri-
be, Stress testing System, Milwaukee, U.S.A.) 
was used to monitor subjects' heart rhythm and 
rate throughout the duration of the test. Sub-
jects exercised on a stationary bicycle ergo-
meter (Cybex Metabolic Systam, Met 100, 
Huntsville, USA) at a constant cadence of 70 
rpm. Increments in intensity occurred each mi-
nute, starting at 35 watts and increasing by 10 
watts each minute. These increments continued 
until the subject was exhausted, or until the 
subject experienced discomfort, or the practi-
tioner observed significant ECG changes. Each 
subjects' oral gas expiration was measured via 
Vacumetric Vista Turbofit Software package 
(Version 3.2, Ametek, Pittsbergh, USA) to de-
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termine their respiratory exchange ratio and 
aerobic capacity. Subjects were deemed to 
have reached their V02 peak when at least two 
of the following criteria were achieved (a) a 
plateau of V02 peak readings over 3 consecu-
tive recordings, (b) exercising heart rate to 
within 10 beats of subjects' maximal heart rate, 
calculated as 220 minus age, (c) a respiratory 
exchange ratio (RER) of greater than 1.10. 
Statistical Analysis 
Data were analysed using SPSS (10.0). 
Data reported are mean ± standard error of the 
mean. Repeated measures analysis of variance 
was used to determine significance. Post-hoc 
analysis of group differences was carried out 
using a Student's unpaired t-test. Significance 
was reported at p < 0.05. 
 
Results 
There was no significant difference in 
age (51.1 ± 2.1 vs. 51.6 ± 1.7 years) and time 
postmenopause (2.3 ± 1.1 vs. 1.6 ± 0.2 years) 
between groups taking hormonal replacement 
therapy and those taking placebo. Similarly, there 
were no significant differences in weight or body 
mass index (BMI) between or within groups 
for the duration of the study (Table 1). Estra-
diol was significantly higher in the HRT group 
in comparison to the placebo group at T2 and 
T3. FSH and LH were significantly decreased 
at T2 and T3 compared with baseline levels in 
the same group (Table 1). The increased estra-
diol and simultaneous significant reduction in 
plasma FSH and LH ascertain that subjects were 
compliant with HRT, which was supported by 
medication counts. Bone resorption markers 
(DPD and PYR) were both significantly reduced 
from baseline levels with HRT administration 
(T2) (Table 1, Figures 1 and 2) and were signifi-
cantly lower than the placebo group at T2. Bone 
resorption markers were unchanged as a result of 
exercise. Although slightly reduced, neither BAP 
nor OC showed significant reductions as a result 
of HRT or exercise. BAP was significantly lower 
than the placebo group at T3. There were no 
significant changes to V02 peak as a result of 
exercise training in  rate, respiratory exchange 
ratio and exercise duration were unchanged in 
both groups as a result of the exercise training 
regimen over a 12 week period. 
 
Table 1 
 
Personal, Hormonal, Fitness and Bone parameters 
 
 Baseline Placebo Placebo & 
exercise 
Baseline HRT HRT & 
exercise 
 T1 T2 T3 T1 T2 T3 
Weight, kg 69.4  4.7 69.7  4.9 69.3  4.8 71.8  7.8 72.1  7.6 72.5  7.5 
BMI, kg/m2 26.8  2.2 26.9  2.3 26.7  2.2 27.5  3.3 27.6  3.2 27.8  3.2 
Estradiol, pmol/l 77.6  12.0 89.2  17.1 73.4  18.3 100.0 2 1.5 166.3  36.8+ 164.9  29.9+ 
FSH, m/u/ml 57.9  9.7 51.1  9.4 56.1  13.5 77.1  14.8 39.8  15.8* 37.1  14.6* 
LH, m/u/ml 45.8  11.8 33.7  7.3 36.2  7.2 44.7  8.9 18.4  6.8* 19.6  8.1* 
AC, ml/kg/min 20.6  1.9 21.2  1.7 21.6  1.7 21.4  2.6 22.3  2.7 22.9  1.9 
BONE 
FORMATION 
      
OC, ug.l 17.3  2.6` 17.9  2.7 17.8  2.4 15.7  3.0 15.2  2.9 14.3  2.8 
BAP, U/L 13.6  2.8 16.8  2.9 16.8  3.1 11.1  3.8 10.6  4.0 9.5  4.1+ 
BONE 
RESORPTION 
      
PYR, 
nmomol/mmol Cr 
81.0  16.9 79.6  15.9 78.1  13.6 75.5  15.6 58.6  12.08*+ 64.9  14.0 
DPD, 
nmmol/mmol Cr 
15.6  3.1 16.0  3.3 14.1  3.0 13.7  3.2 9.9  2.4*+ 9.5  2.7 
Abbreviations: BMI, body mass index; FSH, follicle stimulating hormone; LH, luteinising hormone; AC, aerobic 
capacity: OC, osteocalcin; BAP, bone alkaline phosphatase; PYR, pyridinoline; DPD, deoxypyridionline. 
* (p < 0.05) Significantly different from T1 H group. 
+ (p < 0.05) Significantly different from placebo group at the same time point. 
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Figure 1 – Urinary Pyridinoline (PYR) excretion percent change in placebo (n = 12) and HRT (n = 10) groups from 
baseline levels with hormone or placebo treatment alone and with hormone or placebo treatment and exercise. 
(*significantly different from baseline levels, p < 0.05) 
 
 
 
Figure 2 – Urinary Deoxypyridinoline (DPD) excretion percentage change in placebo (n = 12) and HRT (n = 10) 
groups from baseline levels with treatment alone and with treatment and exercise (*significantly different from 
baseline levels, p < 0.05) 
 
Discussion 
The main new findings of this study were 
that bone resorption indices were significantly 
reduced after 8 weeks of HRT, whilst bone for-
mation markers remained unchanged. Our re-
sults are similar to a previous study [19] that 
found one year of treatment with estrogen sig-
nificantly suppressed bone resorption, whilst 
bone formation remained unchanged, preven-
ting overall bone loss in ovariectomised wo-
men, measured by dual energy x-ray absorptio-
metry (DXA). Furthermore recent studies con-
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ducted in mice shows decreased trabecular thic-
kness, bone density and bone volume and in-
creased trabecular separation caused by ove-
riectomy were prevented by giving estrogen 
replacement [17]. 
Sex hormones play a regulatory role in 
bone metabolism [20]. Estrogen levels correla-
ted with osteoclastic (bone resorption) activity 
thus increased estrogen levels directly increase 
osteoclast apoptosis [21]. Reduced estrogen le-
vels that accompany menopause increase cy-
tokine levels- interleukin-1 and tumor necrosis 
factor alpha, secreted from peripheral blood 
monocytes [22]. These factors act on stromal 
osteoblastic precursor cells, and induce secre-
tion of other cytokines interleukin-6 and inter-
leukin-11, which promote the development of 
bone resorbing osteoclasts [20, 22, 23]. Thus, 
estrogen deprivation provides an indirect sti-
mulus as a potent promoter of bone resorption. 
Combinations of cytokines – interleukin-1, tu-
mor necrosis factor alpha, interferon gamma- 
increases osteoblastic nitric oxide (NO) pro-
duction [24], which suppresses bone resorptive 
osteoclast development and activity, and sub-
sequently reduces resorption. The production 
of NO by osteoblasts directly regulates osteo-
clast activity and is perceived to play a regula-
tory role in conditions of bone such as osteopo-
rosis [l 9l. Estrogen replacement down regula-
tes interleukin-6 production [25, 26] providing 
at least one molecular mechanism for the inhi-
bitory effect of hormonal therapy on postmeno-
pausal bone loss. 
Exercise effect 
Weight-bearing exercise provides a sti-
mulus of mechanical loading on bone cells, 
which induces bone formation [27]. The effect 
of physical activity on human bone has been 
well documented in a variety of population 
groups [28–32]. Younger athletes have a grea-
ter bone mass in comparison to sedentary con-
trols [30]. Dominant arms of male and female 
tennis players exhibit up to 28.4% greater bone 
thickness and bone mineral content in compari-
son to non-dominant arms [31, 32]. The bone 
response to exercise after menopause, however, 
has provided varying degrees of both positive 
results [33, 34], results indicating that varying 
types and intensities of exercise provide no 
training effect on bone [35–37]. In this study, 
moderate weight-bearing exercise alone in the 
form of walking did not alter any bone forma-
tion or resorption indices. The intensity, fre-
quency and duration of exercise are important 
parameters when considering an exercise trai-
ning regimen. Wolff’s law proposes that bone 
remodeling is directly dependent upon the me-
chanical load placed on the bone [38]. Alterna-
tively, a strain threshold may exist for the sti-
mulation of osteogenesis. An insufficient appli-
cation of strain or load may be inadequate to 
reach the strain threshold, indicating that the 
magnitude of the strain may be more important 
than strain frequency. Brisk walking alone may 
provide an insufficient mechanical strain to 
overcome estrogen deficiency after menopause. 
This may explain why, in this study, there was 
no change in bone turnover markers as a result 
of walking based exercise training regimen 
with either HRT or placebo treatment. 
Type and intensity of exercise  
There are numerous studies that assess 
bone mineral changes as a result of exercise in 
postmenopausal populations. The results of these 
studies, however, provide conflicting outcomes. 
Aerobic exercise, involving brisk walking and 
lifetime volleyball involvement, were unable to 
counteract an age and, or, menopause related 
decline in BMD [35, 39]. BMD primarily at the 
femoral neck, however, was increased with exer-
cise that involved vigorous walking, jogging, 
stair climbing, and high impact aerobics [33, 
40, 41] whilst, total body BMD was also aug-
mented [40, 42] in a number of these studies. 
On the other hand, long term vertical jumping 
exercises using a weighted vest prevented hip 
bone loss over five years [43]. High intensity 
aquatic exercise program performed for 24 weeks 
prevented from reducing BMD by increase 
bone formation and reduce bone resorption [44, 
45]. Resistance and strength training performed 
for at least one year increased regional BMD at 
sites of intratrochanter and hip [46], and total 
body [42, 46]. Similar programs that were 
performed for one year or less showed no change 
in total bone mineral content (BMC) [36], BMD 
at lumbar spine [35, 37, 47] or total hip BMD 
[37]. It should be noted that it is difficult to 
compare studies due to the differences in exer-
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cise regimen type, intensity and frequency, and 
subject characteristics such as age, baseline BMD 
and years since menopause. With increasing age 
and years postmenopause, there is an accretion 
in the amount of bone lost; therefore, if women 
are commencing exercise at lower bone den-
sities there may be a greater effect of treatment.  
The age range of the current study was 
very tight, with all women 49 to 54 years of 
age, and early postmenopause (1.6 to 2.3 years) 
and could partly explain the lack of exercise 
effect in the current study, as women were 
commencing exercise prior to having lost 
substantial BMD due to estrogen deficiency. In 
contrast, previous exercise studies had large 
ranges for age and the number of years post-
menopause, with many studies involving wo-
men up to and over 10 years older than women 
in the current study. The exercise program de-
signed for these women was mild and gradua-
ted to minimize the risk that previously seden-
tary women would not encounter injury thro-
ughout the training program. All women remai-
ned injury-free for the duration of their invol-
vement. Walking was chosen as the mode of 
exercise due to the weight-bearing nature and 
ease of administration. It was also perceived 
that previously sedentary women would be more 
compliant with this mode of exercise, which 
was verified by subjects' diarising involvement 
in walking sessions. The moderate nature of the 
exercise program did not increase the V02 peak 
of the subjects, nor alter weight or BMI. 
Vibration exercise is one of the safest 
activities for osteoporosis women that prevent 
falls. Whole-body vibration strategy is used in 
preventing sarcopenia and osteoporosis [48, 
49]. Although no significant improvement in 
BMD were seen in a 6 month vibration training 
[50]; muscle strength was improved [49–51]. 
Combined hormone replacement 
therapy and exercise  
The addition of a brisk walking program 
to HRT, in this population of postmenopausal 
women, provided no additional changes to 
either bone resorption (Figures la. and lb.) or 
formation indices, indicating that HRT was the 
primary stimulus for changes in bone turnover. 
Previous studies focusing on the effects combi-
ned exercise and HRT on BMD have been 
conflicting. Prospective studies [34] have found 
aerobic exercise in combination with HRT, but 
not exercise alone, significantly increased BMD. 
However, current studies have shown high in-
tensity exercise significantly increased BMD in 
postmenopausal women [44, 45]. Hence, any 
benefit conveyed by combined treatment appea-
red to be attributable to HRT. In contrast, HRT 
and nine months of vigorous weight-bearing 
exercise were independently beneficial in increa-
sing BMD, whilst combined treatment provided 
an additive benefit at sites of lumbar spine and 
Wards triangle [33]. HRT and weight lifting 
exercises also significantly increased BMD of 
the total body in women who had had a hyste-
rectomy, but exercise was not assessed inde-
pendently of HRT [52]. There are no studies 
that measure bone turnover markers as a result 
of these combined treatments. 
 
Conclusion 
The current pilot study, although in small 
group numbers indicated that walking alone, at 
the intensities and duration prescribed, was an 
insufficient stimulus to reduce bone turnover in 
early postmenopausal women, whilst HRT was 
an effective treatment intervention to reduce 
bone turnover after menopause. The combina-
tion of HRT and moderate weight bearing exer-
cise provided no added benefit in comparison 
to HRT alone. A combination of resistance tra-
ining and walking may be more effective in 
reducing bone turnover, in comparison to wal-
king alone. Alternatively, older populations of 
postmenopausal women, with lower BMD va-
lues, may benefit more from walking alone. 
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Ре зиме 
 
ЕФЕКТИТЕ НА ХОРМОНСКАТА 
ТЕРАПИЈА И ВЕЖБАЊЕТО ВРЗ 
КОСКЕНИОТ МЕТАБОЛИЗАМ  
КАЈ ЖЕНИ ВО ПОСТМЕНОПАУЗА: 
РАНДОМИЗИРАНА, ДВОЈНО СЛЕПА 
ПИЛОТ-СТУДИЈА 
 
Сузи Ј Хонисет1, Кети Тангалакис1,  
Џон Варк2, Васо Апостолопулос1,  
Лили Стојановска1 
 
1 Центар за хронични болести, Школа за 
здравство и биомедицина, Универзитет 
Викторија, Викторија, Австралија 
2 Кралска болница во Мелбурн, Парквил, 
Мелбурн, Викторија, Австралија 
 
 
Вовед: Хормонска заменска терапија (HRT) 
и пешачење беа испитувани самостојно и во ком-
бинација за да се утврди кој третман најмногу 
влијаел врз коскениот метаболизам кај жени во 
постменопауза.  
Методи: Користејќи рандомизирана двој-
но слепа пилот-студија, 10 испитаници добија 
HRT (трансдермален естрадиол, 50 μg/ден и 
орално MPA 5 mg/ден), a 12 примале плацебо 20 
недели. По почетниот период на третманот, 
двете групи беа подложени на режим на пеша-
чење, што се зголемуваше во интензитет, време-
траење и параметри на зачестеност од 8 до 20 
недели. Мерењата на аеробниот капацитет, жен-
ските полови хормони, маркерите за формирање 
на коските [остеокалцин (OC) и коскена алкална 
фосфатаза (BAP)] и маркерите за коскената ре-
сорпција [деоксипиридинолин (DPD) и пири-
динолин (PYR)] беа мерени на почетокот (Т1), 
8. недела (Т2) и 20. недела (Т3). 
Резултати: Возраста, времето на пост-
менопаузата, тежината или индексот на телесна 
маса не беа различни помеѓу секоја од групите. 
Групата на HRT имаше значително повисоки 
нивоа на естрадиол во споредба со плацебо гру-
пата во Т2 и Т3. Нивоата на FSH и LH беа зна-
чително намалени по HRT. DPD и PYR беа зна-
чително намалени од почетните нивоа на Т2 и 
Т3 со HRT. Немаше значајни промени кај ни-
воата на OC или BAP, со HRT или пешачење. 
Пешачењето не ги промени маркерите на коске-
ниот метаболизам кај HRT или плацебо групата.  
Заклучок: HRT ја намалува коскената ре-
сорпција, сепак, само пешачењето според про-
пишаниот интензитет и времетраењето, или ком-
бинацијата на HRT и пешачење, не дадоа допол-
нителна корист по менопаузата. Затоа, HRT, но 
не и пешачењето, е ефективен третман за нама-
лување на коскениот метаболизам кај жени во 
постменопауза. 
 
Клучни зборови: вежба, хормонска заменска тера-
пија, HRT, коскен метаболизам, менопауза, естроген 
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